There is increasing interest in the use of cannabinoids for disease and symptom
management, but limited information available regarding their pharmacokinetics and …

The use of the intoxicating cannabinoid delta‐8‐tetrahydrocannabinol (Δ8‐THC) has grown
rapidly over the last several years. There have been dozens of Δ8‐THC studies dating back …

Cannabis has a long history of anecdotal medicinal use and limited licensed medicinal use.
Until recently, alleged clinical effects from anecdotal reports and the use of licensed …

Background Globally, medical cannabis legalization has increased in recent years and
medical cannabis is commonly used to treat chronic pain. However, there are few …

Cannabidiol (CBD), the main nonpsychoactive constituent of Cannabis sativa, has shown a
wide range of therapeutically promising pharmacological effects either as a sole drug or in …

Cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, has multiple
pharmacological actions, including anxiolytic, antipsychotic, antiemetic and anti …

The endocannabinoids system (ECS) has garnered considerable interest as a potential
therapeutic target in various carcinomas and cancer-related conditions alongside …

Background The use of cannabis, or marijuana, for medicinal purposes is deeply rooted
though history, dating back to ancient times. It once held a prominent position in the history …

Δ 9-tetrahydrocannabinol binds cannabinoid (CB 1 and CB 2) receptors, which are activated
by endogenous compounds (endocannabinoids) and are involved in a wide range of …

Exogenous cannabinoids are structurally and pharmacologically diverse compounds that
are widely used. The purpose of this systematic review is to summarize the data …